The inexorable increase of biologic exposure in paediatric inflammatory bowel disease: a Scottish, population‐based, longitudinal study-Reference-Cited by-同舟云学术

The inexorable increase of biologic exposure in paediatric inflammatory bowel disease: a Scottish, population‐based, longitudinal study

Published:2022-10-04 Issue:10 Volume:56 Page:1453-1459
ISSN:0269-2813
Container-title:Alimentary Pharmacology & Therapeutics
language:en
Short-container-title:Aliment Pharmacol Ther

Author:

Burgess Christopher J.¹²^ORCID,Jackson Rebecca³,Chalmers Iain⁴,Russell Richard K.²,Hansen Richard⁵,Scott Gregor⁵,Henderson Paul¹²^ORCID,Wilson David C.¹²

Affiliation:

1. Child Life and Health University of Edinburgh Edinburgh UK

2. Department of Paediatric Gastroenterology and Nutrition Royal Hospital for Children and Young People Edinburgh UK

3. Department of Paediatric Gastroenterology and Nutrition Royal Hospital for Children Glasgow UK

4. Department of Paediatric Gastroenterology Royal Aberdeen Children's Hospital Aberdeen UK

5. Department of Paediatric Gastroenterology Royal Hospital for Children Glasgow UK

Publisher

Wiley

Subject

Pharmacology (medical),Gastroenterology,Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/apt.17217

Reference22 articles.

1. Dramatic Increase in Incidence of Ulcerative Colitis and Crohn's Disease (1988–2011): A Population-Based Study of French Adolescents

2. Paediatric Patients (Less Than Age of 17 Years) Account for Less Than 1.5% of All Prevalent Inflammatory Bowel Disease Cases

3. Definition of Phenotypic Characteristics of Childhood-Onset Inflammatory Bowel Disease

4. Twenty-first Century Trends in the Global Epidemiology of Pediatric-Onset Inflammatory Bowel Disease: Systematic Review

5. Rising incidence of pediatric inflammatory bowel disease in Scotland*

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Randomised clinical trial: First‐line infliximab biosimilar is cost‐effective compared to conventional treatment in paediatric Crohn's disease;Alimentary Pharmacology & Therapeutics;2024-04-21

2. An update on dietary therapies in paediatric Crohn's disease;Current Opinion in Clinical Nutrition & Metabolic Care;2024-02-28

3. Sustained Increase in Pediatric Inflammatory Bowel Disease Incidence Across the South West United Kingdom Over the Last 10 Years;Inflammatory Bowel Diseases;2024-02-19

4. Biologic Agents;Contemporary Dental Pharmacology;2024

5. Managing pediatric Crohn’s disease: recent insights;Expert Review of Gastroenterology & Hepatology;2023-10-03